{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:08:57Z","timestamp":1794251337143,"version":"4.9.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical trials are an important therapeutic option for patients with cancer. Although financial burden in cancer treatment is well documented, the financial burden associated with clinical trials is not well understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We conducted a survey regarding economic burden and financial toxicity in patients with cancer enrolled in phase I clinical trials for &amp;gt;1 month. Financial toxicity score was assessed using the Comprehensive Score for Financial Toxicity survey. Patients also reported monthly out-of-pocket (OOP) costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two hundred and thirteen patients completed the survey (72% non-Hispanic White; 45% with annual income \u2264$60,000; 50% lived &amp;gt;300 miles from the clinic; 37% required air travel). Forty-eight percent of patients had monthly OOP costs of at least $1,000. Fifty-five percent and 64% of patients reported unanticipated medical and nonmedical expenses, respectively. Worse financial toxicity was associated with yearly household income &amp;lt;$60,000 (odds ratio [OR]: 2.7; p = .008), having unanticipated medical costs (OR: 3.2; p = .024), and living &amp;gt;100 miles away from the clinical trial hospital (OR: 2.3; p = .043). Non-White or Hispanic patients (OR: 2.5; p = .011) and patients who were unemployed or not working outside the home (OR: 2.5; p = .016) were more likely to report high unanticipated medical costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients with cancer participating in clinical trials, economic burden is high, and most of patients\u2019 OOP costs were nonmedical costs. Financial toxicity is disproportionally higher in patients with lower income and those who travel farther, and unexpected medical costs were more common among non-White or Hispanic patients. OOP costs can be substantial and are often unexpected for patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>The financial burden of cancer treatment is well documented, but there are limited data regarding the financial burden associated with cancer clinical trials. This study surveyed 213 patients enrolled in early-phase clinical trials. Monthly out-of-pocket costs were at least $1000 for nearly half of patients. Worse financial toxicity was associated with income &amp;lt;$60,000 and living farther away from the hospital. Racial\/ethnic minorities had higher rates of unanticipated medical costs. These data help to quantify the high financial burden for patients and may reveal a cause of disparities in clinical trial enrollment for underrepresented populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13767","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:44:45Z","timestamp":1617065085000},"page":"588-596","source":"Crossref","is-referenced-by-count":87,"title":["Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7887-8484","authenticated-orcid":false,"given":"Ryan W.","family":"Huey","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goldy C.","family":"George","sequence":"additional","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Phillips","sequence":"additional","affiliation":[{"name":"Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revenda","family":"White","sequence":"additional","affiliation":[{"name":"Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chen Tina","family":"Shih","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"2022020214132171500_onco13767-bib-0001","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00520-014-2581-9","article-title":"Cancer patient decision making related to clinical trial participation: An integrative review with implications for patients\u2019 relational autonomy","volume":"23","author":"Bell","year":"2015","journal-title":"Support Care Cancer"},{"key":"2022020214132171500_onco13767-bib-0002","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.2015.63.2463","article-title":"Financial concerns about participation in clinical trials among patients with cancer","volume":"34","author":"Wong","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022020214132171500_onco13767-bib-0003","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"The role of clinical trial participation in cancer research: Barriers, evidence, and strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2022020214132171500_onco13767-bib-0004","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2001.19.6.1728","article-title":"Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment","volume":"19","author":"Lara","year":"2001","journal-title":"J Clin Oncol"},{"key":"2022020214132171500_onco13767-bib-0005","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1200\/JCO.2002.08.056","article-title":"How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials","volume":"20","author":"Sateren","year":"2002","journal-title":"J Clin Oncol"},{"key":"2022020214132171500_onco13767-bib-0006","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","volume":"18","author":"Zafar","year":"2013","journal-title":"The Oncologist"},{"key":"2022020214132171500_onco13767-bib-0007","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JOP.2013.001322","article-title":"Impact of financial burden of cancer on survivors\u2019 quality of life","volume":"10","author":"Fenn","year":"2014","journal-title":"J Oncol Pract"},{"key":"2022020214132171500_onco13767-bib-0008","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/annonc\/mdw433","article-title":"The association of financial difficulties with clinical outcomes in cancer patients: Secondary analysis of 16 academic prospective clinical trials conducted in Italy","volume":"27","author":"Perrone","year":"2016","journal-title":"Ann Oncol"},{"key":"2022020214132171500_onco13767-bib-0009","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/EDBK_174893","article-title":"How should we intervene on the financial toxicity of cancer care? One shot, four perspectives","volume":"37","author":"Zafar","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2022020214132171500_onco13767-bib-0010","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1377\/hlthaff.2012.1263","article-title":"Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis","volume":"32","author":"Ramsey","year":"2013","journal-title":"Health Aff (Millwood)"},{"key":"2022020214132171500_onco13767-bib-0011","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022020214132171500_onco13767-bib-0012","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1634\/theoncologist.2017-0628","article-title":"At what cost to clinical trial enrollment? A retrospective study of patient travel burden in cancer clinical trials","volume":"23","author":"Borno","year":"2018","journal-title":"The Oncologist"},{"key":"2022020214132171500_onco13767-bib-0013","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1634\/theoncologist.2019-0146","article-title":"Addressing the financial burden of cancer clinical trial participation: Longitudinal effects of an equity intervention","volume":"24","author":"Nipp","year":"2019","journal-title":"The Oncologist"},{"key":"2022020214132171500_onco13767-bib-0014","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamaoncol.2018.0492","article-title":"Addressing financial barriers to enrollment in clinical trials","volume":"4","author":"Largent","year":"2018","journal-title":"JAMA Oncol"},{"key":"2022020214132171500_onco13767-bib-0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/EDBK_100019","article-title":"Financial toxicity and equitable access to clinical trials","volume":"39","author":"Chino","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2022020214132171500_onco13767-bib-0016","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cncr.30369","article-title":"Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the Comprehensive Score for Financial Toxicity (COST)","volume":"123","author":"Souza","year":"2017","journal-title":"Cancer"},{"key":"2022020214132171500_onco13767-bib-0017","doi-asserted-by":"crossref","DOI":"10.2196\/10348","article-title":"Cancer-related internet use and its association with patient decision making and trust in physicians among patients in an early drug development clinic: A questionnaire-based cross-sectional observational study","volume":"21","author":"George","year":"2019","journal-title":"J Med Internet Res"},{"key":"2022020214132171500_onco13767-bib-0018","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1200\/JOP.2016.016337","article-title":"Determinants of patient-centered financial stress in patients with locally advanced head and neck cancer","volume":"13","author":"Souza","year":"2017","journal-title":"J Oncol Pract"},{"issue":"suppl 3","key":"2022020214132171500_onco13767-bib-0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/jco.2016.34.3_suppl.16","article-title":"Grading financial toxicity based upon its impact on health-related quality of life (HRQol)","volume":"34","author":"Souza","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022020214132171500_onco13767-bib-0020","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.2013.53.0956","article-title":"Long-term financial burden of breast cancer: Experiences of a diverse cohort of survivors identified through population-based registries","volume":"32","author":"Jagsi","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022020214132171500_onco13767-bib-0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/EDBK_100021","article-title":"Enrollment of racial minorities in clinical trials: Old problem assumes new urgency in the age of immunotherapy","volume":"39","author":"Nazha","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2022020214132171500_onco13767-bib-0022","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JOP.19.00102","article-title":"Mind the gap: Precision oncology and its potential to widen disparities","volume":"15","author":"Huey","year":"2019","journal-title":"J Oncol Pract"},{"key":"2022020214132171500_onco13767-bib-0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01132","article-title":"Addressing financial barriers to patient participation in clinical trials: ASCO policy statement","author":"Winkfield","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022020214132171500_onco13767-bib-0024","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jamaoncol.2017.2148","article-title":"Out-of-pocket costs, financial distress, and underinsurance in cancer care","volume":"3","author":"Chino","year":"2017","journal-title":"JAMA Oncol"},{"key":"2022020214132171500_onco13767-bib-0025","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: A cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematol"},{"key":"2022020214132171500_onco13767-bib-0026","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.amjsurg.2019.01.033","article-title":"Financial burden amongst cancer patients treated with curative intent surgery alone","volume":"218","author":"Allcott","year":"2019","journal-title":"Am J Surg"},{"key":"2022020214132171500_onco13767-bib-0027","author":"Internal Revenue Service","year":"2020"},{"key":"2022020214132171500_onco13767-bib-0028","volume-title":"The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Bethesda, MD: Department of Health, Education, and Welfare","author":"National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research","year":"1978"},{"key":"2022020214132171500_onco13767-bib-0029","author":"Food and Drug Administration","year":"2020"},{"key":"2022020214132171500_onco13767-bib-0030","volume-title":"","author":"Relating to a Cancer Clinical Trial Participation Program","year":"2019"},{"key":"2022020214132171500_onco13767-bib-0031","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMsb1710591","article-title":"A framework for ethical payment to research participants","volume":"378","author":"Gelinas","year":"2018","journal-title":"N Engl J Med"},{"key":"2022020214132171500_onco13767-bib-0032","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/jamia\/ocaa067","article-title":"Telehealth transformation: COVID-19 and the rise of virtual care","volume":"27","author":"Wosik","year":"2020","journal-title":"J Am Med Inform Assoc"},{"key":"2022020214132171500_onco13767-bib-0033","volume-title":"FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Public Health Emergency. Silver Spring, MD: Food and Drug Administration","author":"Food and Drug Administration","year":"2020"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13767","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/588\/42367410\/oncolo_26_7_588.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/588\/42367410\/oncolo_26_7_588.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T09:14:46Z","timestamp":1643793286000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/7\/588\/6510466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4,21]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13767","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,4,21]]}}}